Search Results for: PTPRC

58 interactions involving PTPRC - protein tyrosine phosphatase receptor type C found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Symbol Description Pathways Hide Drugs Hide Diseases Hide
CD8A CD8 subunit alpha
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
CSNK2A1 casein kinase 2 alpha 1
  • Synthesis of PC
  • WNT mediated activation of DVL
  • Condensation of Prometaphase Chromosomes
  • Signal transduction by L1
  • Regulation of TP53 Activity through Phosphorylation
  • Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
  • Receptor Mediated Mitophagy
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • Regulation of PTEN stability and activity
  • KEAP1-NFE2L2 pathway
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
  • Maturation of hRSV A proteins
  • SPOP-mediated proteasomal degradation of PD-L1(CD274)
  • Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK
  • Phosphorylation and nuclear translocation of the CRY:PER:kinase complex
  • ATP
  • (5-hydroxyindolo[1,2-a]quinazolin-7-yl)acetic acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Quercetin
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • Emodin
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • Dichlororibofuranosylbenzimidazole
  • Quinalizarin
  • Ellagic acid
  • Fostamatinib
CSNK2A2 casein kinase 2 alpha 2
  • Synthesis of PC
  • WNT mediated activation of DVL
  • Condensation of Prometaphase Chromosomes
  • Signal transduction by L1
  • Regulation of TP53 Activity through Phosphorylation
  • Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
  • Receptor Mediated Mitophagy
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • Regulation of PTEN stability and activity
  • KEAP1-NFE2L2 pathway
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
  • Maturation of hRSV A proteins
  • SPOP-mediated proteasomal degradation of PD-L1(CD274)
  • Phosphorylation and nuclear translocation of the CRY:PER:kinase complex
  • [1-(6-{6-[(1-methylethyl)amino]-1H-indazol-1-yl}pyrazin-2-yl)-1H-pyrrol-3-yl]acetic acid
  • Fostamatinib
CXCR4 C-X-C motif chemokine receptor 4
  • Binding and entry of HIV virion
  • Signaling by ROBO receptors
  • Chemokine receptors bind chemokines
  • G alpha (i) signalling events
  • Formation of definitive endoderm
  • Specification of primordial germ cells
  • Developmental Lineage of Multipotent Pancreatic Progenitor Cells
  • Baclofen
  • Framycetin
  • AMD-070
  • Plerixafor
  • Ulocuplumab
  • Ibalizumab
  • MSX-122
  • Chemokine receptor defect, including the following disease: WHIM syndrome
DPP4 dipeptidyl peptidase 4
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)
  • Atorvastatin
  • Sitagliptin
  • 2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One
  • 5-(Aminomethyl)-6-(2,4-Dichlorophenyl)-2-(3,5-Dimethoxyphenyl)Pyrimidin-4-Amine
  • (2s)-Pyrrolidin-2-Ylmethylamine
  • 4-Iodo-L-phenylalanine
  • Diisopropylphosphono Group
  • 1-(1-phenylcyclopentyl)methylamine
  • (S)-2-[(R)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
  • Vildagliptin
  • PSN9301
  • AMG-222
  • Bisegliptin
  • Alogliptin
  • Saxagliptin
  • (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-PROP-1-YN-1-YLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE
  • N-(TRANS-4-{(1S,2S)-2-AMINO-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-1-METHYL-3-OXOPROPYL}CYCLOHEXYL)-N-METHYLACETAMIDE
  • (2S,3S)-4-cyclopropyl-3-{(3R,5R)-3-[2-fluoro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazolidin-5-yl}-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
  • (2S,3S)-3-{3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-amine
  • (3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinoxalin-2-ylcarbonyl)pyrrolidin-3-amine
  • (7R,8R)-8-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydroimidazo[1,2-a:4,5-c']dipyridin-7-amine
  • (2S,3S)-3-{3-[4-(METHYLSULFONYL)PHENYL]-1,2,4-OXADIAZOL-5-YL}-1-OXO-1-PYRROLIDIN-1-YLBUTAN-2-AMINE
  • (1S,2R,5S)-5-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-2-(2,4,5-TRIFLUOROPHENYL)CYCLOHEXANAMINE
  • (2R)-4-[(8R)-8-METHYL-2-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[1,5-A]PYRAZIN-7(8H)-YL]-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE
  • (2S,3S)-3-AMINO-4-(3,3-DIFLUOROPYRROLIDIN-1-YL)-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-6-YLCYCLOHEXYL)BUTANAMIDE
  • (2S,3S)-3-AMINO-4-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-5-YLCYCLOHEXYL)BUTANAMIDE
  • (3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-METHYL-1,4-DIAZEPAN-2-ONE
  • 4'-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]biphenyl-3-carboxamide
  • (2R,3R)-7-(methylsulfonyl)-3-(2,4,5-trifluorophenyl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-2-amine
  • 7-(aminomethyl)-6-(2-chlorophenyl)-1-methyl-1H-benzimidazole-5-carbonitrile
  • 4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one
  • METHYL 4-{[({[(2R,5S)-5-{[(2S)-2-(AMINOMETHYL)PYRROLIDIN-1-YL]CARBONYL}PYRROLIDIN-2-YL]METHYL}AMINO)CARBONYL]AMINO}BENZOATE
  • (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-ETHYNYLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE
  • 1-biphenyl-2-ylmethanamine
  • (1S,3S,5S)-2-{(2S)-2-amino-2-[(1R,3S,5R,7S)-3-hydroxytricyclo[3.3.1.1~3,7~]dec-1-yl]acetyl}-2-azabicyclo[3.1.0]hexane-3-carbonitrile
  • (2R)-N-[(2R)-2-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-N-[(5R)-5-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-L-PROLINAMIDE
  • (3R,4S)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE
  • N-({(2S)-1-[(3R)-3-AMINO-4-(2-FLUOROPHENYL)BUTANOYL]PYRROLIDIN-2-YL}METHYL)BENZAMIDE
  • (4R,5R)-5-AMINO-1-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-2-ONE
  • (3R,4S)-1-(3,4-DIMETHOXYPHENYL)-3-(3-METHYLPHENYL)PIPERIDIN-4-AMINE
  • 1-[2-(S)-AMINO-3-BIPHENYL-4-YL-PROPIONYL]-PYRROLIDINE-2-(S)-CARBONITRILE
  • ABT-341
  • (2R)-4-(2-BENZOYL-1,2-DIAZEPAN-1-YL)-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE
  • (3R,4R)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-3-AMINE
  • Gosogliptin
  • N-({(2S)-1-[(3R)-3-amino-4-(3-chlorophenyl)butanoyl]pyrrolidin-2-yl}methyl)-3-(methylsulfonyl)benzamide
  • (3R,4S)-1-[6-(6-METHOXYPYRIDIN-3-YL)PYRIMIDIN-4-YL]-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE
  • 6-(4-{(1S,2S)-2-AMINO-1-[(DIMETHYLAMINO)CARBONYL]-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-3-OXOPROPYL}PHENYL)-1H-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-4-IUM
  • 7-BENZYL-1,3-DIMETHYL-8-PIPERAZIN-1-YL-3,7-DIHYDRO-PURINE-2,6-DIONE
  • 2-({2-[(3R)-3-AMINOPIPERIDIN-1-YL]-4-OXOQUINAZOLIN-3(4H)-YL}METHYL)BENZONITRILE
  • 4-[(3R)-3-{[2-(4-FLUOROPHENYL)-2-OXOETHYL]AMINO}BUTYL]BENZAMIDE
  • 2-({8-[(3R)-3-AMINOPIPERIDIN-1-YL]-1,3-DIMETHYL-2,6-DIOXO-1,2,3,6-TETRAHYDRO-7H-PURIN-7-YL}METHYL)BENZONITRILE
  • Linagliptin
  • Dutogliptin
EZR ezrin
  • Netrin-1 signaling
  • Recycling pathway of L1
  • Recycling pathway of L1
  • Sensory processing of sound by inner hair cells of the cochlea
  • Sensory processing of sound by outer hair cells of the cochlea
FCGR3A Fc gamma receptor IIIa
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • FCGR activation
  • FCGR activation
  • Regulation of actin dynamics for phagocytic cup formation
  • Role of phospholipids in phagocytosis
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Cetuximab
  • Etanercept
  • Human immunoglobulin G
  • Gemtuzumab ozogamicin
  • Alemtuzumab
  • Alefacept
  • Palivizumab
  • Daclizumab
  • Bevacizumab
  • Catumaxomab
  • Sarilumab
  • Benralizumab
  • Amivantamab
  • NK cell defects, including the following disease: CD16 deficiency
  • Systemic lupus erythematosus
FYN FYN proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • Signaling by ERBB2
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Cell surface interactions at the vascular wall
  • FCGR activation
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • EPH-Ephrin signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Nephrin family interactions
  • NCAM signaling for neurite out-growth
  • NCAM signaling for neurite out-growth
  • Co-stimulation by CD28
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • Co-inhibition by CTLA4
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • Ephrin signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • CRMPs in Sema3A signaling
  • VEGFA-VEGFR2 Pathway
  • Dectin-2 family
  • CD209 (DC-SIGN) signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Platelet Adhesion to exposed collagen
  • Reelin signalling pathway
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • FLT3 signaling through SRC family kinases
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • Dasatinib
  • Triglyme
  • Fostamatinib
  • Zotiraciclib
GANAB glucosidase II alpha subunit
  • N-glycan trimming in the ER and Calnexin/Calreticulin cycle
  • Calnexin/calreticulin cycle
  • Maturation of spike protein
  • Maturation of spike protein
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
  • Miglitol
GRB2 growth factor receptor bound protein 2
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
IFNAR1 interferon alpha and beta receptor subunit 1
  • Interferon alpha/beta signaling
  • Regulation of IFNA/IFNB signaling
  • Regulation of IFNA/IFNB signaling
  • Potential therapeutics for SARS
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • Evasion by RSV of host interferon responses
  • Peginterferon alfa-2a
  • Interferon alfa-n1
  • Interferon alfa-n3
  • Peginterferon alfa-2b
  • Interferon alfa-2a
  • Interferon beta-1a
  • Interferon beta-1b
  • Interferon alfacon-1
  • Interferon alfa-2b
  • Interferon alfa
  • Human interferon omega-1
  • Peginterferon beta-1a
  • Anifrolumab
  • Human interferon beta
  • Ropeginterferon alfa-2b
INSR insulin receptor
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • IRS activation
  • Signal attenuation
  • Insulin receptor signalling cascade
  • Signaling by Insulin receptor
  • Insulin receptor recycling
  • Insulin human
  • Insulin lispro
  • Insulin glargine
  • Insulin pork
  • Mecasermin
  • Insulin aspart
  • Insulin detemir
  • Insulin glulisine
  • Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate
  • NN344
  • AT1391
  • Linsitinib
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
  • Chromic chloride
  • Insulin beef
  • Insulin degludec
  • Insulin argine
  • Insulin peglispro
  • Insulin tregopil
  • Fostamatinib
  • Brigatinib
  • Mecasermin rinfabate
  • BMS-754807
  • KW-2450 free base
  • Leprechaunism ; Donohue syndrome
  • Rabson-Mendenhall syndrome
IRS1 insulin receptor substrate 1
  • PI3K Cascade
  • IRS-mediated signalling
  • SOS-mediated signalling
  • SOS-mediated signalling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • PI3K/AKT activation
  • PI3K/AKT activation
  • Signaling by ALK
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • IRS-related events triggered by IGF1R
  • Signaling by Leptin
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • IRS activation
  • Signal attenuation
  • Activated NTRK3 signals through PI3K
  • Signaling by ALK fusions and activated point mutants
  • Growth hormone receptor signaling
  • Signaling by LTK
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
ITGAL integrin subunit alpha L
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Cell surface interactions at the vascular wall
  • Integrin cell surface interactions
  • Neutrophil degranulation
  • RUNX3 Regulates Immune Response and Cell Migration
  • Efalizumab
  • Antithymocyte immunoglobulin (rabbit)
  • Lovastatin
  • Simvastatin
  • Rosuvastatin
  • 1-Acetyl-4-(4-{4-[(2-Ethoxyphenyl)Thio]-3-Nitrophenyl}Pyridin-2-Yl)Piperazine
  • LFA703
  • (S)-2-((S)-3-isobutyl-2,5-dioxo-4-quinolin-3-ylmethyl-[1,4]diazepan-1yl)-N-methyl-3-naphtalen-2-yl-propionamide
  • 7A-[(4-cyanophenyl)methyl]-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7A-tetrahydro-1H-pyrrolo[1,2-A]pyrrole-7-carbonitrile
  • 3-({4-[(1E)-3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-2,3-bis(trifluoromethyl)phenyl}sulfanyl)aniline
  • Pitavastatin
  • Lifitegrast
JAK1 Janus kinase 1
  • Interleukin-6 signaling
  • Interleukin-6 signaling
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • ISG15 antiviral mechanism
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Other interleukin signaling
  • RAF/MAP kinase cascade
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • IL-6-type cytokine receptor ligand interactions
  • Interferon gamma signaling
  • Regulation of IFNG signaling
  • Regulation of IFNG signaling
  • Interleukin-20 family signaling
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Interleukin-35 Signalling
  • Interleukin-9 signaling
  • Interleukin-2 signaling
  • Interleukin-12 signaling
  • Interleukin-12 signaling
  • Interleukin-27 signaling
  • Interleukin-27 signaling
  • Interleukin-21 signaling
  • Interferon alpha/beta signaling
  • Interleukin receptor SHC signaling
  • Regulation of IFNA/IFNB signaling
  • Regulation of IFNA/IFNB signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Potential therapeutics for SARS
  • Inactivation of CSF3 (G-CSF) signaling
  • Inactivation of CSF3 (G-CSF) signaling
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • IFNG signaling activates MAPKs
  • Evasion by RSV of host interferon responses
  • PD-L1(CD274) glycosylation and translocation to plasma membrane
  • Myricetin
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • Ruxolitinib
  • Tofacitinib
  • Baricitinib
  • Fostamatinib
  • Fedratinib
  • Filgotinib
  • Abrocitinib
  • Upadacitinib
  • Pralsetinib
  • Ivarmacitinib
JAK2 Janus kinase 2
  • Interleukin-6 signaling
  • Interleukin-6 signaling
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • Prolactin receptor signaling
  • Prolactin receptor signaling
  • Signaling by SCF-KIT
  • Signaling by Leptin
  • RMTs methylate histone arginines
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RAF activation
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • IL-6-type cytokine receptor ligand interactions
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Cyclin D associated events in G1
  • Interferon gamma signaling
  • Regulation of IFNG signaling
  • Regulation of IFNG signaling
  • Interleukin-20 family signaling
  • Interleukin-35 Signalling
  • Signaling by Erythropoietin
  • Signaling by Erythropoietin
  • Interleukin-12 signaling
  • Interleukin-12 signaling
  • Interleukin-23 signaling
  • Interleukin-23 signaling
  • Interleukin-27 signaling
  • Interleukin-27 signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Erythropoietin activates STAT5
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Interleukin receptor SHC signaling
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Potential therapeutics for SARS
  • Inactivation of CSF3 (G-CSF) signaling
  • Inactivation of CSF3 (G-CSF) signaling
  • IFNG signaling activates MAPKs
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
  • Factors involved in megakaryocyte development and platelet production
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • XL019
  • 5-phenyl-1H-indazol-3-amine
  • 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide
  • 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
  • Ruxolitinib
  • Tofacitinib
  • Pacritinib
  • Baricitinib
  • Entrectinib
  • Fostamatinib
  • Fedratinib
  • Abrocitinib
  • Zanubrutinib
  • Pralsetinib
  • Polycythemia vera
JAK3 Janus kinase 3
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by ALK
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • Interleukin-20 family signaling
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Interleukin-9 signaling
  • Interleukin-2 signaling
  • Interleukin-21 signaling
  • Interleukin receptor SHC signaling
  • Potential therapeutics for SARS
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • R-348
  • Ruxolitinib
  • Tofacitinib
  • Baricitinib
  • Fostamatinib
  • Abrocitinib
  • Zanubrutinib
  • T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
LCK LCK proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Nef Mediated CD4 Down-regulation
  • Downstream TCR signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Translocation of ZAP-70 to Immunological synapse
  • Generation of second messenger molecules
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • Co-stimulation by CD28
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • Co-inhibition by CTLA4
  • Co-inhibition by PD-1
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RHOH GTPase cycle
  • Interleukin-2 signaling
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • FLT3 signaling through SRC family kinases
  • Dasatinib
  • AP-22408
  • Staurosporine
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
  • 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
  • N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
  • Ponatinib
  • Nintedanib
  • Fostamatinib
  • Zanubrutinib
  • Zotiraciclib
  • Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
LCP2 lymphocyte cytosolic protein 2
  • GPVI-mediated activation cascade
  • Generation of second messenger molecules
  • Generation of second messenger molecules
  • DAP12 signaling
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
LGALS1 galectin 1
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Post-translational protein phosphorylation
  • Mercaptoethanol
  • Thiodigalactoside
  • 1,4-Dithiothreitol
  • Artenimol
  • OTX-008

Page 2 out of 3 pages